However,it has been suggested that PPARγ ligands couldhave activity in combination with retinoids and/or histone deacetylaseinhibitors in thyroid tumors which express both PPARγ and also RXRγ [93, 94]. The gene discussed is PPARG; the disease is thyroid tumor.